Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7

Journal of Immunotherapy

Volumn 20, Issue 1, 1997, Pages 38-47

  Akagi, Junji ^a   Hodge, James W ^b   McLaughlin, Joanne P ^b   Gritz, Linda ^c   Mazzara, Gail ^c   Kufe, Donald ^d   Schlom, Jeffrey ^b   Kantor, Judith A ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Therion Biologics Corporation   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

B7; Costimulation; MUC1; Vaccine; Vaccinia

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER INHIBITION; GENE TARGETING; HUMAN; IMMUNOSTIMULATION; LUNG CANCER; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN TARGETING; RABBIT; T LYMPHOCYTE ACTIVATION; TARGET CELL DESTRUCTION; VACCINIA VIRUS;

ANIMALS; ANTIGENS, CD80; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; MICE; NEOPLASM METASTASIS; RECOMBINATION, GENETIC; REPETITIVE SEQUENCES, NUCLEIC ACID; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0031451498     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199701000-00004     Document Type: Article

References (32)

1. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lin S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883-93.
2. Neidhart JA, Murphy SG, Hennick LA, Wise HA. Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer 1980;46:1128-34.
3. Hoover HC Jr, Surdyke MG, Dangel RB, Peters LC, Hanna MG Jr. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 1985;55:1236-43.
4. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
5. Hollinshead A, Stewart TH, Takita H, Dalbow M, Concannon J. Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens. Cancer 1987;60:1249-62.
6. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-32.
7. Taylor-Papadimitriou J, Epenetos AA. Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy. Trends Biotechnol 1994;12:227-33.
8. Taylor-Papadimitriou J, D'Souza B, Burchell J, Kyprianou N, Berdichevsky F. The role of tumor-associated antigens in the biology and immunotherapy of breast cancer. Ann N Y Acad Sci 1993;698:31-47.
9. Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res 1993;53:5386-94.
10. Finn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995;145:61-89.
11. Burchell J, Graham R, Taylor-Papadimitriou J. Active specific immunotherapy: PEM as a potential target molecule. Cancer Surv 1993;18:135-48.
12. Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991;51:2908-16.
13. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993;151:3693-703.
14. Barnd DL, Lan MS, Metzgar RS, Finn, OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989;86:7159-63.
15. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995;155:4766-74.
16. Ding L, Lalani EN, Reddish M, et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 1993;36:9-17.
17. Acres RB, Hareuveni M, Balloul JM, Kieny MP. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J Immunother 1993;14:136-43.
18. Bu D, Domenech N, Lewis J, Taylor-Papadimitriou J, Finn OJ. Recombinant vaccinia mucin vector: in vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T-cell recognition. J Immunother 1993; 14:127-35.
19. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res 1995;55:3598-603.
20. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994;54:5552-5.
21. Fox BA, Spiess PJ, Kasid A, et al. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod 1990;9:499-511.
22. Earl PL, Moss B. Generation of recombinant vaccinia viruses, In: Current protocols in molecular biology, vol 2, suppl 21. New York: John Wiley & Sons, 1993:16.17.1-.18.10.
23. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci USA 1988;85:2320-3.
24. Abe M, Siddiqui J, Kufe D. Sequence analysis of the 5′ region of the human DF3 breast carcinoma-associated antigen gene. Biochem Biophys Res Commun 1989;165:644-9.
25. Gritz L, Destree A, Cormier N, et al. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J Virol 1990;64:5948-57.
26. Gillard S, Spehner D, Drillien R, Kirn A. Localization and sequence of a vaccinia virus gene required for multiplication in human cells. Proc Natl Acad Sci USA 1986;83:5573-7.
27. Smith KA, Stallard V, Roos JM, et al. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences. Vaccine 1993;11:43-53.
28. Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 1991;48:900-7.
29. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84:1084-91.
30. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 1966;36:641-5.
31. Sekine H, Ohno T, Kufe DW. Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J Immunol 1985;135:3610-5.
32. Hareuveni M, Gautier C, Kieny MP, Wreschner D, Chambon P, Lathe R. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA 1990;87:9498-502.